<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110040</url>
  </required_header>
  <id_info>
    <org_study_id>TAOIMTIMAGE</org_study_id>
    <nct_id>NCT05110040</nct_id>
  </id_info>
  <brief_title>Multi-model Image of Immunosuppressive Agents in TAO</brief_title>
  <official_title>A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of immunosuppressive agents treating Thyroid&#xD;
      Associated Ophthalmopathy by multi-model image.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid Associated Ophthalmopathy is one of autoimmune orbital diseases characterized by&#xD;
      enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue&#xD;
      volume affecting the appearance and visual function of the eyes. TAO can be classified into&#xD;
      active phase and inactive phase according to the activity score and wait-and-see or surgery&#xD;
      are widely chosen for patients in inactive phase. A great number of patients in inactive&#xD;
      phase becoming refractory and reoccurring.&#xD;
&#xD;
      Until now, the improvement of TAO is still be measured subjectively with low reliability and&#xD;
      less accuracy. Multi-modal image is a new method to assess both the appearance and visual&#xD;
      function of TAO and some of the indexes can be regarded as more apparent and stable in&#xD;
      assessing the efficacy and prognosis of TAO.&#xD;
&#xD;
      This perspective cohort study aims to evaluate the efficacy of immunosuppressive agents in&#xD;
      TAO by multi-model image and function assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>participants diagnosed of TAO administrated with immunosuppressive agents</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Assessors who calculate the changes of the images are masked of the diagnosis and treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change of macular sensibility</measure>
    <time_frame>At 6 months</time_frame>
    <description>the same investigator uses the same instrument to assess the macular sensibility. The better change of macular sensibility means the better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of extraocular muscle volume and orbital fat volume by MRI</measure>
    <time_frame>at month 6</time_frame>
    <description>A 3D MRI reconstructive model will be established and the volume of extraocular muscle and orbital fat will be calculated by the same advanced programmer who is blinded of the pre- or post- treatment images order. The higher the value changes, the better the outcome is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of proptosis</measure>
    <time_frame>at month 6</time_frame>
    <description>proptosis will be measured by the same investigator using the same Hertel instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of QoL</measure>
    <time_frame>at month 6</time_frame>
    <description>the score of quality of life will be assessed by the same investigator using GO-QoL. The higher change of quality of life means the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of eyelid aperture and lid lag</measure>
    <time_frame>at month 6</time_frame>
    <description>the values will be measured by the same investigator using the same millimeter ruler and the higher change of eyelid aperture and lid lag means the better outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Thyroid Associated Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>immunosuppressive agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients recruited will be treated with one or／and two immnuosuppressive agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immunosuppressive agent</intervention_name>
    <description>patients with TAO recruited in this study will administrated with immunosuppressive agent per day</description>
    <arm_group_label>immunosuppressive agents</arm_group_label>
    <other_name>immunosuppressive regulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age 18-70 years old&#xD;
&#xD;
          -  Diagnosed with TAO.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to immunosuppressive agents.&#xD;
&#xD;
          -  Patients with HIV, Hepatitis B or C, Tuberculosis or other active significant&#xD;
             infection.&#xD;
&#xD;
          -  Patients with severe chronic diseases in heart, lung, kidney and liver, which make it&#xD;
             not tolerant to immunosuppressive agents.&#xD;
&#xD;
          -  Patients have contraindications of MRI(metal pacemaker, fake teeth, foreign body and&#xD;
             other materials which will disturb the examination).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Liang</last_name>
    <phone>（86）-87330402</phone>
    <email>liangdan@gzzoc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxi Chen</last_name>
    <phone>（86）-87330402</phone>
    <email>chenyx293@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang</last_name>
      <phone>（86）-87330402</phone>
      <email>liangdan@gzzoc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>Dan Liang, PhD</investigator_title>
  </responsible_party>
  <keyword>Thyroid Associated Ophthalmopathy</keyword>
  <keyword>Immunosuppressive agents</keyword>
  <keyword>multi-modal image</keyword>
  <keyword>function assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

